2011
Significance of Pathologic Response to Preoperative Therapy in Pancreatic Cancer
Chun YS, Cooper HS, Cohen SJ, Konski A, Burtness B, Denlinger CS, Astsaturov I, Hall MJ, Hoffman JP. Significance of Pathologic Response to Preoperative Therapy in Pancreatic Cancer. Annals Of Surgical Oncology 2011, 18: 3601-3607. PMID: 21947697, DOI: 10.1245/s10434-011-2086-4.Peer-Reviewed Original ResearchConceptsPathologic response ratePathologic responsePreoperative therapyPancreatic adenocarcinomaResponse rateComplete pathologic response rateMajor pathologic response rateMajor pathologic responseNegative lymph nodesImportant prognostic factorMinority of patientsSmaller tumor sizeMedian survival rateR0 resectionConsecutive patientsPancreatic headPartial responsePrognostic factorsImproved survivalLymph nodesTumor sizeHistopathologic examinationMinor responsePancreatic cancerTherapy occurs
2010
Defining Venous Involvement in Borderline Resectable Pancreatic Cancer
Chun YS, Milestone BN, Watson JC, Cohen SJ, Burtness B, Engstrom PF, Haluszka O, Tokar JL, Hall MJ, Denlinger CS, Astsaturov I, Hoffman JP. Defining Venous Involvement in Borderline Resectable Pancreatic Cancer. Annals Of Surgical Oncology 2010, 17: 2832-2838. PMID: 20725860, DOI: 10.1245/s10434-010-1284-9.Peer-Reviewed Original ResearchConceptsR0 resection ratePreoperative therapyPreoperative chemoradiationResection ratePancreatic adenocarcinomaVenous involvementBilateral narrowingUnilateral narrowingSurvival rateBorderline resectable pancreatic adenocarcinomaBorderline resectable pancreatic cancerMargin-negative resection rateMedian overall survival rateHigher R0 resection rateImproved overall survivalResectable pancreatic cancerNegative lymph nodesMargin-negative resectionOverall survival rateResectable pancreatic adenocarcinomaSuperior mesenteric veinPreoperative computed tomographyType IIBackgroundPancreatic adenocarcinomaBorderline resectability
2009
Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy
Faller BA, Burtness B. Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy. Biologics: Targets And Therapy 2009, Volume 3: 419-428. PMID: 19774209, PMCID: PMC2747340, DOI: 10.2147/btt.s3170.Peer-Reviewed Original ResearchEpidermal growth factor receptorPancreatic cancerAdvanced diseaseEpidermal growth factor receptor-targeted therapyDevelopment of rashFirst-line agentsAppropriate patient selectionReceptor-targeted therapyEGFR inhibitor erlotinibInduction of angiogenesisGrowth factor receptorSurvival benefitPatient selectionCommon malignancyPredictive factorsAvailable therapiesPancreatic adenocarcinomaClinical trialsInhibitor erlotinibLimited efficacyTreatment efficacyUnquestioned roleTumor proliferationTherapyPreclinical research
2006
2111 ECOG 1200: A Randomized Phase II Trial of Gemcitabine Plus Radiotherapy vs Gemcitabine, 5-Fluorouracil and Cisplatin Followed by Radiotherapy and 5-Fluorouracil in Patients With Locally Advanced, Potentially Resectable Pancreatic Adenocarcinoma
Landry J, Catalano P, Hoffman J, Staley C, Harris W, Burtness B, Frontiera M, Berlin J, Benson A. 2111 ECOG 1200: A Randomized Phase II Trial of Gemcitabine Plus Radiotherapy vs Gemcitabine, 5-Fluorouracil and Cisplatin Followed by Radiotherapy and 5-Fluorouracil in Patients With Locally Advanced, Potentially Resectable Pancreatic Adenocarcinoma. International Journal Of Radiation Oncology • Biology • Physics 2006, 66: s272. DOI: 10.1016/j.ijrobp.2006.07.515.Peer-Reviewed Original ResearchVascular endothelial growth factor, FLT‐1, and FLK‐1 analysis in a pancreatic cancer tissue microarray
Chung GG, Yoon HH, Zerkowski MP, Ghosh S, Thomas L, Harigopal M, Charette LA, Salem RR, Camp RL, Rimm DL, Burtness BA. Vascular endothelial growth factor, FLT‐1, and FLK‐1 analysis in a pancreatic cancer tissue microarray. Cancer 2006, 106: 1677-1684. PMID: 16532435, DOI: 10.1002/cncr.21783.Peer-Reviewed Original ResearchConceptsPancreatic cancer tissue microarrayCancer tissue microarrayTissue microarrayVEGF receptor 1Flt-1Receptor 1Kaplan-Meier survival curvesVascular endothelial growth factor (VEGF) expressionIndependent prognostic factorVascular endothelial growth factorFlk-1Growth factor expressionEndothelial growth factorPrimary antibodyFlt-1 expressionOverall survivalPrognostic factorsWorse survivalAggressive diseaseDisease stagePoor prognosisTumor expressionPancreatic cancerPancreatic adenocarcinomaPrincipal receptor